Overview

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

Randomized phase III, multicentre, open label clinical trial to compare pevonedistat in combination with azacytidine versus azacytidine alone, which can be considered a standard of care for patients with newly diagnosed acute myeloid leukemia not eligible for intensive chemotherapy (thus not eligible for an allogeneic hematopoietic stem cell transplant.

Phase:

Phase 3

Details

Lead Sponsor:

PETHEMA Foundation

Collaborators:

Dynamic Science S.L.
Millennium Pharmaceuticals, Inc.

Treatments:

Azacitidine
Pevonedistat